Select status:
Sort by:
Filter by expected publication date

Please enter a valid month/year e.g. 01/2015

Pick a date between March 2000 and February 2026

Filter by area of interest
Filter by type
Showing 1 to 10 of 659
Title Type Expected publication date
Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897] Technology appraisal guidance Expected publication date:TBC 0
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839] Technology appraisal guidance Expected publication date:TBC 0
3C Patch System for treating diabetic foot ulcers (MT539) Medical technologies guidance Expected publication date:19 January 2022 20220119
Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147 Technology appraisal guidance Expected publication date:TBC 0
Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy ID1347 Technology appraisal guidance Expected publication date:TBC 0
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727] Technology appraisal guidance Expected publication date:TBC 0
Abicipar pegol for treating wet age-related macular degeneration ID1533 Technology appraisal guidance Expected publication date:TBC 0
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945] Technology appraisal guidance Expected publication date:TBC 0
Acalabrutinib for untreated and treated chronic lymphocytic leukaemia [ID1613] Technology appraisal guidance Expected publication date:21 April 2021 20210421
Acne Vulgaris: Management NICE guideline Expected publication date:09 June 2021 20210609